133 related articles for article (PubMed ID: 38605250)
1. Avoiding Shots in the Dark: Learning from the Past To Inform the Implementation of Long-Acting Injectable Pre-Exposure Prophylaxis for Black American Cisgender Women.
Irie WC; Mayer K
AIDS Behav; 2024 Jul; 28(7):2175-2182. PubMed ID: 38605250
[TBL] [Abstract][Full Text] [Related]
2. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
3. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
[TBL] [Abstract][Full Text] [Related]
4. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.
Okafor CN; Eaton L; Watson R
AIDS Behav; 2024 Jun; 28(6):2166-2174. PubMed ID: 38526639
[TBL] [Abstract][Full Text] [Related]
5. Adapting Provider Training and Pre-Exposure Prophylaxis Advertising to Increase Pre-Exposure Prophylaxis Awareness and Uptake Among Black Cisgender Women.
Devlin SA; Ridgway JP; Dawdani A; Enaholo OE; Liegeon G; Kasal N; Pyra M; Hirschhorn LR; Simon J; Haider S; Ducheny K; Johnson AK
AIDS Patient Care STDS; 2023 Dec; 37(12):574-582. PubMed ID: 38011350
[TBL] [Abstract][Full Text] [Related]
6. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.
Cole SW; Glick JL; Campoamor NB; Sanchez TH; Sarkar S; Vannappagari V; Rinehart A; Rawlings K; Sullivan PS; Bridges JFP
BMJ Open; 2024 Apr; 14(4):e083837. PubMed ID: 38653510
[TBL] [Abstract][Full Text] [Related]
7. EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP).
Kaul CM; Moore BE; Kaplan-Lewis E; Casey E; Pitts RA; Pagan Pirallo P; Lim S; Kapadia F; Cohen GM; Khan M; Mgbako O
PLoS One; 2023; 18(9):e0291657. PubMed ID: 37725628
[TBL] [Abstract][Full Text] [Related]
8. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
[TBL] [Abstract][Full Text] [Related]
9. Social and structural factors associated with interest in HIV preexposure prophylaxis among Black women in the United States.
Irie WC; Calabrese SK; Mayer KH; Geng EH; Blackstock O; Marcus JL
AIDS Care; 2024 May; 36(5):672-681. PubMed ID: 38176016
[TBL] [Abstract][Full Text] [Related]
10. Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States.
Keddem S; Thatipelli S; Caceres O; Roder N; Momplaisir F; Cronholm P
J Acquir Immune Defic Syndr; 2024 Apr; 95(4):370-376. PubMed ID: 38133586
[TBL] [Abstract][Full Text] [Related]
11. High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.
Paudel K; Gupta S; Gautam K; Wickersham JA; Khati A; Azwa I; Ha T; Shrestha R
J Community Health; 2023 Jun; 48(3):513-521. PubMed ID: 36732459
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States.
Aaron E; Blum C; Seidman D; Hoyt MJ; Simone J; Sullivan M; Smith DK
AIDS Patient Care STDS; 2018 Jan; 32(1):16-23. PubMed ID: 29323558
[TBL] [Abstract][Full Text] [Related]
13. PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States.
Chapman Lambert C; Marrazzo J; Amico KR; Mugavero MJ; Elopre L
J Assoc Nurses AIDS Care; 2018; 29(6):835-848. PubMed ID: 29685648
[TBL] [Abstract][Full Text] [Related]
14. UPDOs Protective Styles, a Multilevel Intervention to Improve Pre-exposure Prophylaxis Uptake Among Black Cisgender Women: Pretest-Posttest Evaluation.
Randolph SD; Johnson R; Jeter E; McGee K; Johnson A
J Assoc Nurses AIDS Care; 2023 Sep-Oct 01; 34(5):459-468. PubMed ID: 37651624
[TBL] [Abstract][Full Text] [Related]
15. POWER Up-Improving pre-exposure prophylaxis (PrEP) uptake among Black cisgender women in the Southern United States: Protocol for a stepped-wedge cluster randomized trial (SW-CRT).
Ridgway JP; Devlin SA; Friedman EE; Enaholo OE; Pyra M; Hirschhorn LR; Haider S; Ducheny K; Johnson AK
PLoS One; 2023; 18(5):e0285858. PubMed ID: 37196008
[TBL] [Abstract][Full Text] [Related]
16. Identifying Implementation Strategies to Enhance HIV Pre-Exposure Prophylaxis Uptake Among Black Cisgender Women in New Orleans, Louisiana.
Clement ME; Perry B; McKenna K; Beckford J; Davenport T; Murray E; Magee V; Bickham JN; Siren J; Smith A; Lillis R; Corneli A
AIDS Patient Care STDS; 2024 Mar; 38(3):144-150. PubMed ID: 38471093
[TBL] [Abstract][Full Text] [Related]
17. Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men.
Patel RR; Crane JS; López J; Chan PA; Liu AY; Tooba R; James AS
PLoS One; 2018; 13(12):e0209484. PubMed ID: 30592756
[TBL] [Abstract][Full Text] [Related]
18. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.
Marshall BDL; Goedel WC; King MRF; Singleton A; Durham DP; Chan PA; Townsend JP; Galvani AP
Lancet HIV; 2018 Sep; 5(9):e498-e505. PubMed ID: 29908917
[TBL] [Abstract][Full Text] [Related]
19. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
Maloney KM; Le Guillou A; Driggers RA; Sarkar S; Anderson EJ; Malik AA; Jenness SM
J Infect Dis; 2021 Jan; 223(1):72-82. PubMed ID: 32882043
[TBL] [Abstract][Full Text] [Related]
20. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs.
Biello KB; Edeza A; Salhaney P; Biancarelli DL; Mimiaga MJ; Drainoni ML; Childs ES; Bazzi AR
AIDS Care; 2019 Oct; 31(10):1214-1220. PubMed ID: 30822103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
